Skip to main content

AnaptysBio, Inc.

corporate_fare Company Profile

AnaptysBio, Inc.

ANAB·NASDAQ·Life Sciences·CIK 0001370053

ANAPTYSBIO, INC is a clinical-stage biotechnology company that develops immunology therapeutics for autoimmune and inflammatory diseases. The company's clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, which completed a Phase 2b trial for moderate-to-severe rheumatoid arthritis (RA). ANB033, a CD122 antagonist, is in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE). ANB101, a BDCA2 modulator, is in a Phase 1a trial. ANAPTYSBIO, INC also discovered and out-licensed multiple therapeutic antibodies through financial collaborations. These include a PD-1 antagonist, Jemperli (dostarlimab-gxly), licensed to GSK, and an IL-36R antagonist, imsidolimab, licensed to Vanda Pharmaceuticals Inc. The company currently generates revenue from milestones and royalties under its immuno-oncology collaboration with GSK and from license and transition services revenue from its collaboration with Vanda. In September 2025, the company announced plans to explore separating its business into two independent, publicly traded companies. One company is expected to manage the financial collaborations for Jemperli from GSK and imsidolimab from Vanda, focusing on protecting and returning royalty value to shareholders. The other company is expected to be a clinical-stage biotechnology company focused on developing and potentially commercializing innovative therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033, and ANB101. This proposed separation is expected to be completed in the second quarter of 2026.

AnaptysBio, Inc. (NASDAQ:ANAB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 46 items for ANAB at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • AnaptysBio Soars to 52-Week High Post-Spinoff; First Tracks Biotherapeutics Shares Decline
  • AnaptysBio Approves Spin-Off of First Tracks Biotherapeutics, Authorizes $100M Buyback, and Appoints Key Director
  • $145M Private Placement Secured for AnaptysBio's Spin-Off, First Tracks Biotherapeutics
  • AnaptysBio Posts $49.6 Million Net Income in Q4
  • AnaptysBio to Spin Off Biopharma Unit as First Tracks Biotherapeutics in Q2 2026 to Unlock Value

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$234.6M
Net Income
-$13.23M
Diluted EPS
-$0.46
Op. Cash Flow
$19.7M
Free Cash Flow
$19.61M
Operating Income
$47.9M
Cash & Equivalents
$238.2M
Debt / Equity
0.00×
Net Margin
-5.6%
Shares Outstanding
28.02M sh
Source: 10-K · filed 2026-04-28 · accession 0001193125-26-187044
$46.63
52-week range · as of 2026-11-19 $22.06 – $72.36
Market cap
$1.39B
Volume
432.4K (1.0× avg)
3-mo avg 429.8K
Live data · 2026-11-22 11:06 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ANAB - Filings & News (Page 3)

ANAB
Apr 20, 2026, 1:15 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $50.42
Real-time Price: $46.63 info
Change: -$3.78 (-8%) info
Market Cap: $1.386B info
ANAB
Mar 27, 2026, 9:19 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $64.02
Real-time Price: $46.63 info
Change: -$17.39 (-27%) info
Market Cap: $1.386B info
ANAB
Mar 27, 2026, 9:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $64.20
Real-time Price: $46.63 info
Change: -$17.57 (-27%) info
Market Cap: $1.386B info
ANAB
Mar 03, 2026, 4:15 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $52.83
Real-time Price: $46.63 info
Change: -$6.20 (-12%) info
Market Cap: $1.386B info
ANAB
Mar 03, 2026, 4:15 PM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $52.83
Real-time Price: $46.63 info
Change: -$6.20 (-12%) info
Market Cap: $1.386B info
ANAB
Jan 09, 2026, 5:17 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $44.67
Real-time Price: $46.63 info
Change: +$1.96 (+4%) info
Market Cap: $1.386B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets